Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma

Launched by EASTERN HEPATOBILIARY SURGERY HOSPITAL · Jan 26, 2009

Keywords

ClinConnect Summary

Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more than 28%. The TACE treatment, under the theoretical basis of blood supply of Liver cancer, is obviously better than the other non-surgical therapy, in terms of tumor regression, AFP decrease, survival time and the evaluation of the quality of life. Licartin injection is a antibody drug with new target and the only drug that China own the intellectual property rights. It has specific high affinity with HAb18G/CD147, the liver cell membrane antigen. Labeled 131I is taken to the liver tissue, owning high...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. the participation is entirely voluntary, good at compliance, sign the informed consent form in person;
• • 2. diagnosed to be hepatocellular carcinoma by clinical method, imaging method and tumor markers; and the surgeons determine who can not undergo surgery;
• • 3. confirmed to recurrent after surgery by pathology;
• • 4. KPS score of physical state ≥ 60 points;
• • 5. liver function is Child-Pugh A or B class
• Exclusion Criteria:
• • 1. General situation is poor and liver function Child-Pugh is C class;
• • 2. there is a serious heart, kidney and blood system diseases in patients;
• • 3. poor compliance;
• • 4. there is allergy history of biological agents or in a state of allergy;
• • 5. pregnancy and breast-feeding women